Search Results 1871-1880 of 19665 for hemoglobin

1. Neurology - Clinical trials - Mayo Clinic

   In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

2. Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed By Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance In Treatment-Naïve Mantle Cell Lymphoma - Mayo Clinic

   Hemoglobin ≥ 8 g/dL and independent of transfusion within 7 days of screening. Platelets ≥ 100 x109/L, or ≥ 50 x109/L if bone marrow involvement, and ...

3. Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working - Mayo Clinic

   - Hemoglobin ≥ 9 g/dL (within ≤ 28 days prior to registration). * No transfusions ≤ 14 days before cycle 1 day 1 (C1D1). - Total bilirubin ≤ 1.5 x ULN ...

4. Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL (within 30 days prior to registration);; Note: The use of transfusion is acceptable; Creatinine clearance (CrCl) > 30 mL/min (within 30 ...

5. Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer - Mayo Clinic

   * hemoglobin ≥ 9g/dL (without use of erythropoietin; without packed RBC transfusion within preceding 2 weeks) * platelet count ≥100,000/?cL * total ...

6. A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) - Mayo Clinic

   Hemoglobin ≥ 90 g/L (9.0 g/dL). Patients may be transfused to meet this criterion. AST, ALT, and ALP ≤ 2.5 x upper limit of normal (ULN); Serum bilirubin ...

7. A Phase 2/3 Study To Investigate The Safety And Efficacy Of Brepocitinib In Adults With Lichen Planopilaris (ALPINE) - Mayo Clinic

   Hemoglobin < 10 g/dL (100 g/L);. Platelet count < 100 × 109 /L (< 100,000/mm3 );. Absolute neutrophil count (ANC) < 1.5 × 109 /L (< 1500/mm3 );. Absolute ...

8. Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). - Mayo Clinic

   Adequate organ and marrow function as defined below: Hemoglobin ≥9.0 g/dL without transfusion 4 weeks prior to the screening and randomization: Absolute ...

9. Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes (REVITALIZE 1) - Mayo Clinic

   Current persistent anemia, defined as hemoglobin \<10g/dL 27. Use of anticoagulation therapy (e.g., warfarin, coumadin, or novel oral anticoagulants \[NOACs ...

10. A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies - Mayo Clinic

    Hemoglobin ≥8.0 g/dL (Grade ≤2) maintained for ≥2 weeks from any prior transfusion. Note: In Part 2 (Cohort Expansion), Grade ≥3 neutropenia ...